Revolution Medicines, Inc. is a pharmaceutical company based in the United States that specializes in developing precision oncology therapies targeting elusive growth pathways such as RAS and mTOR. With a high ESG risk rating score of 34.0, Revolution Medicines is at high risk in terms of environmental, sustainability, and governance factors. Their product portfolio includes innovative treatments like RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.